212 EFFECTS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ON THE EARLY DEVELOPMENT AND POLYSPERMY RATE OF OVINE EMBRYOS PRODUCED IN VITRO

2009 ◽  
Vol 21 (1) ◽  
pp. 204
Author(s):  
H. Luo ◽  
X. Cao ◽  
Y. Zhao ◽  
P. Zhou ◽  
G. Shi
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Treatment Group ◽  
Early Development ◽  
Control Group ◽  
Vascular Endothelial ◽  
Maturation Medium ◽  
Group A ◽  
Group B ◽  
Endothelial Growth Factor

To investigate the effect of vascular endothelial growth factor (VEGF) on the early development and polyspermy rate of ovine embryos in vitro, 2 experiments were conducted with human recombinant VEGF165 supplemented to the media during maturation, fertilization, and culture in vitro, respectively. Ovaries were collected from ewes at a local slaughterhouse. All oocytes surrounded by a multilayer of cumulus cells were collected and rinsed 3 times in maturation medium (control medium and treatment medium, respectively). A total of 100 oocytes in each group were cultured in 4-well plates (Nunc) containing 800 μL of maturation medium at 38.5°C in an atmosphere of 5% CO2 with saturated humidity. Four replicates of each experiment were conducted. Statistical analyses were conducted by ANOVA with SPSS 12.0 software (SPSS Inc., Chicago, IL, USA). Data are expressed as means, and P < 0.05 was considered significant. In Experiment 1, to investigate the effect of VEGF on the early development of ovine embryos in vitro, VEGF was used at 5 ng mL–1 (treatment group A) and 10 ng mL–1 (treatment group B) in maturation medium (TCM-199 + BSA), HSOF fertilization medium, and SOF culture medium. The results showed that the maturation rate was increased significantly (P < 0.01), from 75.76% in the control treatment to 83.98 and 80.23% in treatment group A and treatment group B, respectively. The cleavage rate was increased from 75.85% in the control group to 79.39% in treatment group A (P > 0.05). The development rates of morulae (45.03%) and blastocysts (23.54%) in treatment group A were significantly higher (P < 0.01) than those in the control group (38.94 and 18.09%, respectively). In addition, the development rates of blastocysts in treatment group B (21.05%) were lower than those in treatment group A (P > 0.05) and higher than those in the control group (P > 0.05). In Experiment 2, to investigate the effect of VEGF on the polyspermy rate of ovine embryos in vitro, 5 ng mL–1 of VEGF was used in TCM-199 + BSA maturation medium in this experiment. The results showed that the fertilization rate after 18 h of IVF was increased significantly (P < 0.01), from 75.75% in the control group to 83.86% in the treatment group, and that the polyspermy rate was decreased significantly (P < 0.01), from 12.64% in the control group to 7.68% in the treatment group. These results indicate that VEGF significantly improved the maturation and fertilization rates of ovine oocytes and, consequently, the rate of embryo development in vitro, especially when the medium was supplemented with 5 ng mL–1 of VEGF. The VEGF obviously decreased the polyspermy rate and bated the phenomenon of polyspermy in the process of ovine oocyte IVF. The present study was supported by the National Natural Science Foundation of China (No. 30371035).

Effect of HylocereusPolyrhizus Rind Extract Toward Interleukin-1β, Vascular Endothelial Growth Factor Expression, Endometriosis Implant Area

2017 ◽  
Vol 9 (08) ◽  
Author(s):  
YanuarEka P. ◽  
Hendy Hendarto ◽  
Widjiati .
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Treatment Group ◽  
Negative Control Group ◽  
Negative Control ◽  
Control Group ◽  
Vascular Endothelial ◽  
Mice Model ◽  
Endothelial Growth Factor ◽  
Fruit Rind

Retrograde menstruation lead to I Kappa B Kinase (IKK) fosforilation in peritoneum macrophage and cause secretion of proinflammatory cytokine interleukin1β then stimulate endometriosis cell to produce Vascular Endothelial Growth Factor which lead to increasing of endometriosis lession seen as endometriosis implant area. Cytokine secretion was inhibited through prevention of NF-κB activation by dragon red fruit rind extract (Hylocereuspolyrhizus). The aim of this reserach is to know the effect of dragon red fuit rind extract with 0,25; 0,5; and 1 mg/g bodyweight dosage toward IL-1β, VEGF expression and implant area in endometriosis mice model. The design of this experiment was randomized post test only control group design.Endometrios mice model were made in 14 days and split into two group, positive control group and treatment group after two week negative control group and postive control group were given Na-CMC 0,5% solution consequetively, and treatment group were given dragon red fruit extract with different dosage. Signification number for IL-1β is p>0,05, signification number for VEGF is p>0,05, and implant area signification number is p>0,05. Administration of dragon red fruit rind extract can decrease IL-1β, VEGF, and implant area.

99 EFFECT OF VASCULAR ENDOTHELIAL GROWTH FACTOR ON IN VITRO-PRODUCED PORCINE OOCYTES AND THEIR SUBSEQUENT DEVELOPMENT: A PARTHENOGENETIC STUDY

2008 ◽  
Vol 20 (1) ◽  
pp. 130
Author(s):  
D. Biswas ◽  
J. H. Lee ◽  
E. B. Jeung ◽  
E. S. Lee ◽  
S. H. Hyun
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Inner Cell Mass ◽  
Formation Rate ◽  
Cell Mass ◽  
Vascular Endothelial ◽  
Blastocyst Formation ◽  
Group B ◽  
Endothelial Growth Factor

The addition of vascular endothelial growth factor (VEGF) to maturation media has beneficial effects on oocyte maturation and blastocyst formation (Einspanier et al. 2002 Mol. Reprod. Dev. 62, 29–36). The present study was conducted to examine the effect of parthenogenesis on in vitro-matured porcine oocytes with VEGF along with porcine follicular fluid in the maturation media. Porcine ovaries were collected from a local slaughter house in physiological saline. After aspiration, COC were matured in vitro in TCM-199 supplemented with 10 ng mL–1 of epidermal growth factor and (1) Group A: 10% pFF; (2) Group B: 10% pFF and 5 ng mL–1 of VEGF; (3) Group C: 10% polyvinyl alcohol; or (4) Group D: 5 ng mL–1 of VEGF plus 10% polyvinyl alcohol. Fifty COC were cultured for the first 22 h at 390�C in a humidified atmosphere of 5% CO2 in 95% air with 4 IU mL–1 of eCG and 4 IU mL–1 of hCG. They were then transferred to hormone-free medium and cultured for an additional 20 h. After culture, COC were denuded with hyaluronidase, and a proportion were stained with Hoechst 33342 for evaluating the metaphase II stage. The remaining oocytes were subjected to electrical parthenogenesis by using a 1-mm fusion chamber and were activated by applying 2 direct current pulses of 110V for 60 µs. Cleavage and blastocyst formation rate were evaluated under a stereomicroscope at 48 and 168 h after activation, respectively. Blastocyst quality was assessed by differential staining of inner cell mass and trophectoderm cells according to a modified staining procedure (Thouas et al. 2001 Reprod. Biomed. Online 3, 25–29). All data are presented as mean � SD and were analyzed by ANOVA followed by Duncan's multiple range test using SPSS 12.0 (SPSS Inc., Chicago, IL, USA). The maturation rate was significantly higher (P < 0.05) in Groups A and B than Groups C and D (76.1 � 9.6, 78.9 � 6.0 v. 60. � 14.2 and 58.3 � 14.3, respectively). The cleavage rate was significantly higher (P < 0.05) in Groups A and B (73.2 � 1.8 and 64.6 � 1.1, respectively) than Groups C and D (47.9 � 1.8 and 48.3 � 1.7, respectively). The blastocyst formation rate was significantly higher (P < 0.05) in Group B (32.6 � 2.4) compared to other groups. There was no significant difference in blastocyst cell number (inner cell mass or trophectoderm) among these groups. These data indicate that the exogenous VEGF along with pFF in the maturation media helps to increase the blastocyst formation rate in vitro, and it might be due to presence of some ligand/protein kinase in the pFF that plays an important role during the cyclic growth of oocytes.

Abstract 419: Cytokine-Mediated Release of Vascular Endothelial Growth Factor and Stromal-Derived Factor 1 Induces Neovascularization and Prevents Left Ventricular Remodeling in a Porcine Model of Ischemia Reperfusion.

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Franca S Angeli ◽  
Sarah Jahn ◽  
Nicolas Amabile ◽  
Gina Orcino ◽  
Mia Shapiro ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Treatment Group ◽  
Left Ventricular ◽  
Control Group ◽  
Lv Function ◽  
Vascular Density ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
The Impact

Cytokine therapy has been suggested to improve left ventricle (LV) function after myocardial infarction (MI). The mechanisms for this benefit remain debatable. We investigated the impact of a prolonged combined therapy with Darbepoetin alfa (DARB) and Granulocyte Colony-Stimulating Factor (G-CSF) on LV function and vascular density after MI, correlating it with circulating progenitor cells (CPC), Vascular Endothelial Growth Factor (VEGF) and Stromal-Derived Factor 1 (SDF-1) release. Methods and Results : MI was induced in swine by a 90 minutes balloon occlusion of the left anterior descending artery. Animals were divided between treatment group with DARB-GCSF combination therapy (bolus of DARB 0.9 and GCSF 10ug/kg IV at time of reperfusion, followed by 5 doses of GCSF 5ug/kg SC from day 5 to 9, and four doses of 0.45ug/kg DARB SC once per week starting at day 1, n = 8) or control group (saline injections, n = 8). White blood cells (WBC), CPC, defined by CD45, CD31, CD90 and SLA-1 expression, and circulating levels of VEGF and SDF-1 were assessed at baseline (T0), 1 (T1), 2 (T2), and 3 (T3) weeks post-MI. LV function was assessed by echocardiography at T0, T1 and T6 (6 weeks post-MI), and vascular density by histology at T6. MI size was the same in both groups by post-MI CPK peak and LV ejection fraction (EF) at T1 (41+/−1 vs. 40+/−2%). In the treatment group only, from T0 to T1, there was an increase in WBC (16 ± 2 to 42 ± 2 x 10 6 /ml, p <0.01) and CPC (5 ± 1 to 9 ± 1 x 10 5 /ml, p = 0.01) and SDF-1 levels peaked from T0 to T2 (1345+/−60 to 1554 +/− 60 pg/ml; p<0.01) and stabilized at T3. All these values remained unchanged in the control group. VEGF levels (pg/ml) peaked at T2 in both groups (14+/−1 vs. 12+/−1), but remained increased at T3 in DARB-GCSF group only (13+/−1 vs. 9+/−1; p<0.01). LVEF (41+/−1 vs. 33+/−1, p<0.01) and arteriole density at the infarct zone (44+/−14 vs. 27+/−12/mm 2 , p = 0.02) and remote zone (18 +/−8 vs.11+/−5, p = 0.055) were higher compared to the control at T6. Conclusion : Our data suggest that prolonged therapy with DARB-GCSF combination after MI modulates angiogenesis and promotes stabilization of LV function by increasing CPC, and releasing SDF-1 and VEGF. This therapy provides a novel strategy to prevent post-MI LV remodeling and potentially improve outcome.

The sFLT-1 to PlGF Ratio is Impaired in Patients with Thalassemia and Sickle Cell Disease.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 2010-2010 ◽  
Author(s):  
Ioannis Papassotiriou ◽  
Alexandra Kouraklis-Symeonidis ◽  
Filia Apostolakou ◽  
Athanassios Akalestos ◽  
Vlassis Vlazakis ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Control Group ◽  
Vascular Endothelial ◽  
Cell Disease ◽  
Group A ◽  
Endothelial Growth Factor ◽  
Plgf Ratio

Abstract Abstract 2010 Poster Board I-1032 Background: Placental growth factor (PlGF) is a member of the vascular endothelial growth factor family and is associated with inflammation and with pathologic angiogenesis. PlGF is released from marrow erythroid cells. Serum PlGF concentrations have been reported to be elevated in patients with sickle cell disease. The fms-like tyrosine kinase-1 or sFlt-1 is a soluble form of vascular endothelial growth factor receptor-1 (VEGF-R1), which binds to and sequesters circulating free vascular endothelial growth factor (VEGF) and free PlGF, thereby neutralizing their pro-angiogenic effects. PlGF and VEGFR-1 are key molecules in regulating the angiogenic switch during pathological conditions maintaining the proangio-and anti-angiogenic balance. Perturbations of this balance leads to various degree of endothelial dysfunction, a common pathology in patients with hemoglobinopathies and specifically induce pulmonary hypertension (PHT). In this study we assessed the PlGF and sFLT-1 levels in patients with hemoglobinopathies at steady state. Patients and Methods: One hundred twenty three patients with hemoglobinopathies and 20 apparently healthy individuals were included in the study divided in groups as follows: Group A: 38 patients with thalassemia intermedia; Group B: 41 patients with transfusion-dependent beta-thalassemia; Group C: 33 patients with beta-thallassemia/sickle cell disease (SCD) Group D: 11 patients with beta-thallassemia and clinical evidence of PHT, and; Group E: 20 individuals served as control group In patients and controls we performed measurements of PlGF and sFLT-1 with fully automated electrochemiluminescence assays using the immunochemistry autoanalyzer Roche cobas e411. This method provides rapid and reliable assessments and follow-up of patients any time in the day compared to immunoenzymatic assays. Results: We found that: a) serum PlGF levels were increased in all groups of patients compared to controls (42.7±19.9 pg/mL, 49.9±23.4 pg/mL, 27.5±9.4 pg/mL, 58.1±27.6 pg/mL for group A, B, C and D, respectively vs 17.1±3.9 pg/mL for control group, p<0.001), b) serum sFLT-1 levels were also increased in all groups of patients compared to controls (89.3±18.3 pg/mL, 90.2±24.0 pg/mL, 89.4±15.3 pg/mL, 117.2±43.5 pg/mL, respectively vs 76.7±11.1 pg/mL, p<0.001 for control group and c) sFLT-1 to PlGF ratio was decreased in all groups of patients compared to controls (2.4±0.9, 2.2±1.2, 3.5±1.0, 2.2±0.8, respectively vs 4.7±1.1 for control group, p<0.001. The most significant changes were found in patients with PHT. Conclusions: These findings indicate that patients with thalassemia syndromes and SCD appear to have increased degree of angiogenesis, which is more pronounced in patients with thalassemia compared to patients with SCD and markedly increased in patients with PHT. The decreased sFLT-1/PlGF ratio in almost all patients suggest that the proangio-and anti-angiogenic system is shifted towards to proangiogenic state, providing evidence that patients with hemoglobinopathies even in the steady phase have altered angiogenic state and low-grade inflammation. The results are in accordance to those published earlier for SCD (Blood, 2008;112:856-865.), where the authors demonstrated that PlGF levels were intrinsically elevated due to the increased red cell turnover and may contribute to inflammation and PHT seen in the disease. Disclosures: No relevant conflicts of interest to declare.

Hypoxia-inducible expression of vascular endothelial growth factor for the treatment of spinal cord injury in a rat model

2007 ◽  
Vol 7 (1) ◽  
pp. 54-60 ◽  
Author(s):  
Byung Hyune Choi ◽  
Yoon Ha ◽  
Xian Huang ◽  
So Ra Park ◽  
Joonho Chung ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Vascular Endothelial Growth Factor ◽  
Expression System ◽  
Control Group ◽  
Vascular Endothelial ◽  
Vegf Expression ◽  
Locomotor Recovery ◽  
Cord Injury ◽  
Endothelial Growth Factor

Object Vascular endothelial growth factor (VEGF) has been investigated as a therapy for many disorders and injuries involving ischemia. In this report, we constructed and evaluated a hypoxia-inducible VEGF expression system as a treatment for spinal cord injury (SCI). Methods The hypoxia-inducible VEGF plasmid was constructed using the erythropoietin (Epo) enhancer with the Simian virus 40 (SV40) promoter (pEpo-SV-VEGF) or the RTP801 promoter (pRTP801-VEGF). The expression of VEGF in vitro was evaluated after transfection into N2A cells. The plasmids were then injected into rat spinal cords with contusion injuries. The expression of VEGF in vivo was measured using reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay. Locomotor recovery in the rats was evaluated using the Basso, Beattie and Bresnahan (BBB) scale for locomotor analysis. Results In vitro transfection showed that pEpo-SV-VEGF or pRTP801-VEGF induced VEGF expression under hypoxic conditions, whereas pSV-VEGF did not. The VEGF level was higher in the pEpo-SV-VEGF and pRTP801-VEGF groups than in the control group. The VEGF expression was detected in neurons and astrocytes of the spinal cord. Locomotor recovery was improved in the pEpo-SV-VEGF and pRTP801-VEGF groups, and BBB scores were higher than in the control group. Staining using terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-end labeling showed that the number of apoptotic cells decreased in the plasmid-injected groups compared with the control group, and significant differences were observed between the hypoxia-responsive groups and the pSV-VEGF group. Conclusions These results suggest that the hypoxia-inducible VEGF expression system may be useful for gene therapy of SCI.

scholarly journals Evaluation of vascular endothelial growth factor and nitric oxide associated with resveratrol supplementation

2021 ◽  
Vol 31 (Supplement_2) ◽  
Author(s):  
Armando Caseiro ◽  
Carla Ferreira ◽  
Ana Margarida Silva ◽  
João Paulo Figueiredo ◽  
Telmo Pereira
Keyword(s):  
Nitric Oxide ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Intervention Group ◽  
Study Groups ◽  
Control Group ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Abstract Background Resveratrol (3,4',5-trihydroxystilbene) (RSV) is one of the main non-flavonoid natural polyphenol compounds. Evidence suggests that RSV has a key role in preventing a variety of pathological processes because of its benefits, including anti-aging, anti-inflammatory, and cardiovascular disease prevention. Vascular endothelial growth factor (VEGF) is responsible for vasculogenesis and angiogenesis, and its expression is influenced by RSV. Vascular nitric oxide (NO) acts to relax smooth muscle cells by preventing thrombogenic processes. It has been shown in vitro and in vivo that RSV is involved in NO metabolism. The aim of this work was evaluate the effects of regular low-dose RSV consumption by determining serum VEGF and NO levels compared to a control group. Methods The study involved 27 clinically healthy individuals, divided into a control group (placebo) and an intervention group, supplemented with 100mg RSV/day. The VEGF levels were determined by slot blot technique and NO levels were determined by spectrophotometry before (T0) and after 30 days (T1) of supplementation. Results The VEGF and NO levels slightly decrease from T0 to T1 moment in both study groups, showing a higher decrease in both parameters in the control group compared to the intervention group, but the variation was not statistically significant. Conclusions Daily supplementation with RSV is associated with benefits at the VEGF level as well as at the vascular level. However, further studies with a larger number of participants are needed to confirm the effects of RSV on VEGF and NO levels.

scholarly journals Observation of the Expression of Vascular Endothelial Growth Factor and the Potential Effect of Promoting Hair Growth Treated with Chinese Herbal BeauTop

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Chien-Ying Lee ◽  
Chun-Hung Su ◽  
Chien-Ying Chiang ◽  
Chun-Nan Wu ◽  
Yu-Hsiang Kuan
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Treatment Group ◽  
Hair Growth ◽  
Potential Effect ◽  
Hair Follicles ◽  
Control Group ◽  
Vascular Endothelial ◽  
Chinese Herbal ◽  
Endothelial Growth Factor ◽  
Hair Coverage

Despite minoxidil and finasteride already being approved by the Food and Drug Administration (FDA) for the treatment of hair loss, it is important to identify new and innovative treatments for hair loss, such as looking for a solution in Chinese herbal medicine. One such treatment to consider is BeauTop (BT), whose primary ingredients include Panax japonicus (T.Nees), C.A. Mey. (Araliaceae), Astragalus membranaceus (Fisch) Bunge (Fabaceae), Angelica sinensis (Oliv.) Diels (Apiaceae), Ligustrum lucidum W.T. Aiton (Oleaceae), Rehmannia glutinosa (Gaertn.) DC. (Plantaginaceae), and Eclipta prostrata (L.) L. (Compositae). The aim of this study was to evaluate whether BT can promote hair growth in C57BL/6 mice and to investigate hair coverage, the expression of vascular endothelial growth factor (VEFG), and the numbers of hair follicles in growth phase after oral administration. A total of 12 C57BL/6 mice were divided into two groups: control group and treatment group BT. BT was administered orally as an extract at a volume of 0.6 g/kg. The control group was treated with distilled water. Each group was treated once a day for 12 consecutive days. To observe the expression of VEGF distribution, the number of hair follicles and the hair coverage were examined on days 4, 8, and 12. By comparing the treatment group and control group, we found that VEGF in the BT group on day 8 presented with a higher area percentage than the control group ( p value = 0.003). Hair follicle counting results showed that the BT group was significantly higher than the control group on day 8 ( p value = 0.031). Furthermore, hair coverage was shown to be significantly increased in the treatment group BT on day 8 ( p value = 0.013). Taken together, these results suggest that Chinese medicine (BT) possesses the potential effect of promoting hair growth through VEGF expression. VEGF is considered the most important mediator for the process of angiogenesis involved in hair growth development.

scholarly journals Changes in the Systemic Expression of Sirtuin-1 and Oxidative Stress after Intravitreal Anti-Vascular Endothelial Growth Factor in Patients with Retinal Vein Occlusion

Biomolecules ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. 1414
Author(s):  
De-Kuang Hwang ◽  
Yuh-Lih Chang ◽  
Tai-Chi Lin ◽  
Chi-Hsien Peng ◽  
Ke-Hung Chien ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Gene Expression ◽  
Vascular Endothelial Growth Factor ◽  
Treatment Group ◽  
Sirtuin 1 ◽  
Control Group ◽  
Vascular Endothelial ◽  
Observation Group ◽  
Systemic Oxidative Stress ◽  
Endothelial Growth Factor

Objectives: Retinal vein occlusions (RVO) are associated with systemic risk factors. However, the ocular occlusive events might also influence a patient’s systemic condition. This study tried to investigate serum biomarkers associated with oxidative stress, before and after intravitreal anti-vascular endothelial growth factor (aVEGF) therapy in patients with RVOs. Methods: Newly-onset RVO patients were categorized into two groups: comorbid with macular edema requiring aVEGF therapy (treatment group) and no edema (observation group). Age and sex-matched patients (who received cataract surgery) were included as the control group. Intravitreal ranibizumab with a pro-re-nata regimen were administered. Serum samples were collected prior to treatment, at 6 and 12 months after therapy/observation and were collected once before controls who received cataract surgery. mRNA expression of sirtuin-1, its downstream genes, anti-oxidative biomarkers, and proinflammatory cytokines were measured. Results: There were 32, 26, and 34 patients enrolled in the treatment, observation, and control groups, respectively. The expressions of sirtuin-1 and its downstream genes were significantly lower in patients with RVO compared with the control group. Sirtuin-1 gene expression increased after 1 year of aVEGF therapy in the treatment group but remained unchanged in the observation group. Biomarkers of oxidative stress and proinflammatory cytokines were reduced after 1 year of aVEGF therapy. These biomarkers remained with no changes in the observation group. Conclusions: Our study showed that the systemic oxidative stress increased in RVO patients. The aVEGF therapy could alter the gene expression of anti-oxidative proteins and reduce systemic oxidative stress in these patients.

Sign in / Sign up

Export Citation Format

Share Document